ABSTRACT. The Canadian Inflammatory Myopathy Study (CIMS) is a multicenter prospective cohort recruiting in 8 centers across Canada. One of the aims of CIMS is to conduct and participate in clinical trials in autoimmune inflammatory myopathies (AIM). Conducting clinical trials in rare diseases such as AIM presents challenges. During this symposium, experts in the field presented different solutions to successfully conduct clinical trials in AIM, including the importance of collaboration and careful trial design, as well as training and mentoring of young investigators. (J Rheumatol First Release June 15, 2020; doi:10.3899/jrheum.200480)

Key Indexing Terms: POLYMYOSITIS INCLUSION BODY MYOSITIS CLINICAL TRIALS

The Canadian Inflammatory Myopathy Study (CIMS) group held its second national symposium in Montreal, Canada, on December 6, 2019. The goal was to develop capacity to conduct and participate in clinical trials in autoimmune inflammatory myopathies (AIM). The meeting was organized by Drs. Marie Hudson (chair), Océane Landon-Cardinal, and Valérie Leclair. The event was attended by 11 rheumatologists, 1 neurologist, 1 pediatric rheumatologist, 1 pediatric neurologist, 1 neuropathologist, 1 respirologist, 1 physiotherapist, 1 nurse clinician, 2 patient research partners, 2 non-medical scientists, and 3 representatives of the pharmaceutical industry. The symposium was sponsored by a Canadian Initiative for Outcomes in Rheumatology care (CIORA) grant, the McGill Interdisciplinary Initiative in Infection and Immunity (MI4), and industry.

The CIMS cohort was inspired by a strong Canadian commitment to collaborative research in rheumatic diseases. It was created and enrolled its first subjects in 2014. This pan-Canadian multicentered prospective cohort has now recruited more than 230 AIM subjects from 8 sites across Canada. Data are collected annually and entered into a central database for the purpose of epidemiological and discovery research. The next goal for the study group is to conduct and participate in clinical trials in autoimmune inflammatory myopathies.

From the Department of Medicine, McGill University; Division of Rheumatology, Jewish General Hospital; Department of Medicine, Université de Montréal; Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal, Montreal, Canada; Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA; University of British Columbia and Arthritis Research Canada, Vancouver, British Columbia; Department of Pediatrics, London Children’s Hospital; University of Western Ontario, London, Ontario; Faculty of Medicine and HPME Dalla Lana School of Public Health, University of Toronto; Division of Rheumatology, The Hospital for Sick Children, Toronto, Ontario; Corbus Pharmaceutical Holdings Inc., Norwood, Massachusetts, USA; Lady Davis Institute, Montreal; Department of Medicine, Université de Laval; Division of Rheumatology, Centre Hospitalier Universitaire de Québec, Quebec City; Montreal Neurological Institute, McGill University; Division of Rheumatology, Hôpital du Sacré-Coeur, Montreal, Québec, Canada.

As part of the supplement 2019 Canadian Inflammatory Myopathy Study Symposium, this report was reviewed internally and approved by the Guest Editors for integrity, accuracy, and consistency with scientific and ethical standards.

This symposium was funded by a Canadian Initiative for Outcomes in Rheumatology care (CIORA) grant and the McGill Interdisciplinary Initiative in Infection and Immunity, as well as unrestricted educational grants from Grifols, Corbus Pharmaceuticals, Bristol-Myers Squibb, Sanofi, and Pfizer.

V. Leclair, MD, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital; O. Landon-Cardinal, MD, Department of Medicine, Université de Montréal, and Division of Rheumatology and Research Center, Centre Hospitalier de l’Université de Montréal; R. Aggarwal, MD, MSc, Division of Rheumatology and Clinical Immunology, Department of Medicine, University of Pittsburgh School of Medicine; N. Bansback, PhD, University of British Columbia and Arthritis Research Canada; C. Campbell, MD, Department of Pediatrics, London Children’s Hospital, University of Western Ontario; B.M. Feldman, MD, MSc, Faculty of Medicine and HPME Dalla Lana School of Public Health, University of Toronto, and Division of Rheumatology, The Hospital for Sick Children; M. Jarry, Patient Advocate, Corbus Pharmaceutical Holdings Inc.; S. McNamara, PhD, Corbus Pharmaceutical Holdings Inc.; B. White, MD, Corbus Pharmaceutical Holdings Inc.; M. Hudson, MD, MPH, Department of Medicine, McGill University, and Division of Rheumatology, Jewish General Hospital, and Lady Davis Institute.

Address correspondence to Dr. V. Leclair, Division of Rheumatology, Jewish General Hospital, 3755 chemin de la Côte-Sainte-Catherine, Montreal, Quebec H3T 1E2, Canada. E-mail: valerie.leclair@mcgill.ca
is to develop capacity to conduct and participate in clinical trials in AIM.

Martin Jarry and Suzan McNamara, 2 patient advocates, opened the symposium. They emphasized the importance of patient advocacy in rare diseases and how this could shape the research agenda, even that of industry\(^9\). With an overall incidence of 8–18 cases/million/year and a prevalence of 14–30 cases/100,000, AIM is a rare disease\(^7\). At the moment, most industry-sponsored clinical trials in adult AIM do not include Canadian sites. Canadian patients with AIM are thus at a considerable disadvantage regarding early access to potentially novel therapeutic interventions. Yet Canada has strengths that could help attract industry, including a favorable exchange rate. The challenges of conducting clinical trials in Canada and possible solutions were examined throughout the symposium and are summarized in Table 1.

Collaboration facilitates translational research and accelerates access to clinical trials for patients with neuromuscular diseases. TREAT-NMD is an example of a global network in neuromuscular diseases offering an infrastructure to connect researchers, clinicians, patients, and industry worldwide\(^8\). The chair of the TREAT-NMD Global patient registry, Dr. Craig Campbell, outlined its multifaceted approach to clinical trials facilitation including training and education as well as guidance for study planning. The global registry also serves as a link to easily locate centers that could be sites for any given trial, benefiting both patients and industry. A key message from this session was that it is important for research groups to identify common goals and to build their network infrastructure around them, because a desire to cover too much ground can lead to failure.

Dr. Brian Feldman, a pediatric rheumatologist and clinician-researcher, shared his experience conducting clinical trials in AIM. The pediatric rheumatology community has been a leader in successful collaborative networks such as the Childhood Arthritis and Rheumatology Research Alliance (CARRA) and the Pediatric Rheumatology International Trials Organisation (PRINTO) and has played a major role in the International Myositis Assessment and Clinical

Table 1. Challenges of conducting autoimmune inflammatory myopathies (AIM) clinical trials in Canada.

<table>
<thead>
<tr>
<th>Challenge</th>
<th>Possible Solution</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limited resources</td>
<td>Consider innovative trial designs (e.g., pragmatic trials, patient-centered outcomes). Facilitate recruitment using established AIM registries.</td>
</tr>
<tr>
<td>Regulatory agencies</td>
<td>Partner with regulators to develop and validate outcome measures that meet their requirements.</td>
</tr>
<tr>
<td>Inexperienced investigators</td>
<td>Mentor young investigators to increase capacity. Create and maintain easily accessible training resources.</td>
</tr>
<tr>
<td>Complex outcome measures</td>
<td>Develop and validate AIM subset-driven outcome measures that can be easily interpreted.</td>
</tr>
</tbody>
</table>

Dr. Rohit Aggarwal, an adult rheumatologist and clinician researcher, discussed trial design and outcome measures in AIM. He presented the strengths and limitations of the 2016 American College of Rheumatology/European League Against Rheumatism criteria for clinical response in dermatomyositis and polymyositis\(^14\). Notably, he discussed the pitfalls of the core set measures including the manual muscle testing (operator dependent, ceiling effect) and global activity visual analog scales (subjective, assessing several constructs at once). Dr. Aggarwal discussed newer outcome measures that could be easier to implement in a busy clinical practice such as physical activity monitors, physical function testing (e.g., Sit-to-Stand, 6-minute walk test, and timed up and go) as well as devices to obtain more objective measures of muscle strength, such as handheld dynamometers\(^15,16\). Dr. Aggarwal proposed the idea of a Myositis Clinical Trial Consortium that would have as a primary goal facilitating multicentered clinical trials in AIM. In a similar manner as TREAT-NMD, this consortium would facilitate planning and collaboration between different centers and would support clinical trial readiness by mentoring junior investigators, sharing standard operating procedure, and developing classification criteria/outcome measures.

Dr. Nick Bansback, a health economist, described emerging methods to co-design trials in collaboration with patients. The need for alternatives to traditional trial design has emerged from the increasing recognition that a lot of resources are invested in trials investigating treatments that many patients do not want, either through the treatment characteristics (mode of delivery, side-effect profile) or trial outcomes that are not sufficient to guide a patient’s treatment decisions. In AIM, where patients and resources are scarce, patient-centered approaches could ensure optimal management of resources. While patient-reported outcomes are important and of interest for regulatory agencies, they do not always reflect patient preferences or priorities. Dr. Bansback explained the basis of patient-centered trial designs using examples from studies in rheumatoid arthritis and systemic sclerosis\(^17,18\).

Finally, Dr. Barbara White, chief medical officer for Corbus Pharmaceuticals, gave an industry perspective on conducting clinical trials in rare diseases. Dr. White acknowledged the need for new treatments in AIM, but pointed out that the rarity of the disease, the lack of consensus on classification criteria, and the complexity of the outcome measures.
were major challenges for industry sponsors as well as regulators. Dr. White emphasized that well-trained and committed site investigators and research personnel were key to raising industry interest and conducting successful trials. The importance for the AIM community to develop valid outcome measures that are meaningful to the patient and regulatory agencies was also discussed.

Some main points should be considered to achieve clinical trial readiness in AIM. First, collaboration was mentioned throughout the presentations and the speakers gave several examples of successful networks facilitating clinical trials in rare diseases. Second, planning and trial design, both traditional and innovative, were mentioned as crucial for successful clinical trials. Third, training and mentoring young investigators to provide them with the tools to meet sponsors’ expectations and encourage them to invest in research were deemed to be essential.

ACKNOWLEDGMENT

REFERENCES